Distinction of human immunodeficiency virus type 1 neutralization and infection enhancement by human monoclonal antibodies to glycoprotein 120.
about
Comparison of human immunodeficiency virus (HIV)-specific infection-enhancing and -inhibiting antibodies in AIDS patients.Pathogenesis of human immunodeficiency virus infectionAntibody-Dependent Enhancement of Hepatitis C Virus InfectionMutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes.A weak neutralizing antibody response to hepatitis C virus envelope glycoprotein enhances virus infectionA novel antibody-dependent cellular cytotoxicity epitope in gp120 is identified by two monoclonal antibodies isolated from a long-term survivor of human immunodeficiency virus type 1 infectionEnhancement of human immunodeficiency virus type 1 envelope-mediated fusion by a CD4-gp120 complex-specific monoclonal antibody.Association of HIV neutralizing antibody with lower viral load after treatment interruption in a prospective trial (A5170).Enhancement of feline immunodeficiency virus (FIV) infection after DNA vaccination with the FIV envelope.Independent variation and positive selection in env V1 and V2 domains within maternal-infant strains of human immunodeficiency virus type 1 in vivoHIV-1 gp120: a novel viral B cell superantigen.Detection of IgA-binding sites on human immunodeficiency virus type-1 envelope glycoproteins, Gp120 and Gp41.
P2860
Q24538755-0064BCBD-13B6-43A0-9BF2-79BD8FFD3C61Q24634681-9D6BB78E-BB8C-4674-A186-459440360912Q27485451-AC0C7987-EB43-41C6-A934-2590581CC3A3Q33783763-211CCDB2-706B-41B2-A854-E37E8F380590Q34009510-F56496B4-2C6E-4374-88F6-165BC0B7D80BQ35876233-3B5F2636-B54E-41D6-9AC7-63E95E4D03E8Q35890076-6951F852-8585-467E-8911-6CD0E1ECA0CBQ36421569-5A3735A0-C530-4E79-A90C-D2ED50DC7B4FQ36549107-69326990-6B93-4AD6-A8F0-0073C9BA8457Q36649929-CB7D8433-A9E0-4048-8506-0A3B58B78EEBQ38524329-346F8CBB-E0AB-4B63-B1AC-B1F240D1B19FQ45281480-3AAF74DE-C11F-492E-AEA9-630D3002519E
P2860
Distinction of human immunodeficiency virus type 1 neutralization and infection enhancement by human monoclonal antibodies to glycoprotein 120.
description
1992 nî lūn-bûn
@nan
1992 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Distinction of human immunodef ...... ntibodies to glycoprotein 120.
@ast
Distinction of human immunodef ...... ntibodies to glycoprotein 120.
@en
Distinction of human immunodef ...... ntibodies to glycoprotein 120.
@nl
type
label
Distinction of human immunodef ...... ntibodies to glycoprotein 120.
@ast
Distinction of human immunodef ...... ntibodies to glycoprotein 120.
@en
Distinction of human immunodef ...... ntibodies to glycoprotein 120.
@nl
prefLabel
Distinction of human immunodef ...... ntibodies to glycoprotein 120.
@ast
Distinction of human immunodef ...... ntibodies to glycoprotein 120.
@en
Distinction of human immunodef ...... ntibodies to glycoprotein 120.
@nl
P2093
P2860
P356
P1476
Distinction of human immunodef ...... ntibodies to glycoprotein 120.
@en
P2093
P2860
P304
P356
10.1172/JCI115802
P407
P577
1992-06-01T00:00:00Z